From the sound of it, the doc gave Leronlimab to a critical female patient and she made a remarkable improvement. But once she was stabilized and moved elsewhere, to another doc’s care, the patient went back on SOC (and no longer received Leronlimab) then subsequently passed away.

We could have 10,000 Leronlimab stories like this and the FDA would say “Anecdotal. Who cares?”